Abraham Zangen

In 2020, the FDA granted clearance for a different version of this technology for smoking cessation.

In 2018, the FDA granted de novo clearance to deep transcranial magnetic stimulation as a non-invasive treatment for OCD, after being cleared for treatment-resistant major depressive disorder in 2013.

Zangen has won prizes for his scientific achievements, among them the Medical Futures Innovation Award in the field of Mental Health and Neuroscience, UK, in 2007, the Sieratzki Prize for Advances in Neuroscience in 2010, the Juludan Research Prize in 2015 and the annual Innovation Award of Ben Gurion University in 2019.

In 2003, Zangen returned to Israel and established a laboratory at the Weizmann Institute of Science, where he attained the rank of associate professor in 2010. In 2012 he joined the faculty of Ben-Gurion University of the Negev as an associate professor and was made a full professor in 2015.

During his postdoc at the NIH, Zangen was part of a team that invented a magnetic coil called the "H coil" for use in transcranial magnetic stimulation (TMS); the coil allows deeper penetration of the magnetic field into the brain and the procedure wherein the H-coil was applied to TMS became known as "deep TMS". The H-coil was patented by the NIH in 2002, and was licensed by the startup company Brainsway in 2003. He has continued to do research on applications for deep TMS.

Abraham Zangen was born in Jerusalem. He earned his B.Sc in pharmacology from the Hebrew University and his PhD from the Bar Ilan University in Israel in 1999. He then did a postdoc at the U.S. National Institutes of Health (NIH), which ended in 2003.

Abraham Zangen (Hebrew: אברהם צנגן, born 1969) is an Israeli professor of neuroscience, head of the brain stimulation and behavior lab and chair of the psychobiology brain program at Ben-Gurion University of the Negev (BGU).